Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Tate & Lyle inks $1.7-billion PE deal for commercial sweeteners stake

Published 12/07/2021, 07:24
Updated 12/07/2021, 12:00
© Reuters. The factory of Tate & Lyle Sugars is seen in London, Britain January 27, 2021. REUTERS/Peter Cziborra

© Reuters. The factory of Tate & Lyle Sugars is seen in London, Britain January 27, 2021. REUTERS/Peter Cziborra

By Yadarisa Shabong

(Reuters) -Tate & Lyle said on Monday it will sell a controlling stake in its commercial sweeteners unit to a private equity firm in a deal valuing the new standalone business at $1.7 billion including debt as it focuses on healthier food and drinks.

U.S.-based KPS Capital Partners and Tate & Lyle (LON:TATE), one of the world's biggest producers of sweeteners, will each own 50% of the new company, with the private equity firm having operational and board control.

The deal comes after a flurry of private equity interest in British companies, including for supermarket group Morrisons, driven by cheap valuations due in part to the pandemic and Brexit.

Tate & Lyle shares rose 2.6% in morning trade as the company said it would return 500 million pounds ($695.00 million) to shareholders upon completion of the deal.

Jefferies analysts said details of the split, talks of which were first disclosed by the company in April, were in line with its expectations.

Tate & Lyle will focus on its food and beverage business that makes low-sugar, low-calorie ingredients that go into drinks, soups, sauces and bakery, while the new company will produce plant-based products for food and industrial markets.

"With the pandemic accelerating the trend towards healthier food, now is the right time to focus our business on capturing this growth," Tate & Lyle Chief Executive Nick Hampton said.

The new company will consist of the primary products business in the Americas that makes bulk sweeteners, industrial starches and animal nutrition, and an interest in its Almex and Bio-PDO joint ventures. The smaller European operations would remain with Tate & Lyle, it said.

The company said the deal would see it substantially cut its exposure to commodities markets and bulk ingredients in North America.

The split is expected to complete in the first quarter of 2022 following approval from shareholders and regulators.

($1 = 0.7194 pounds)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.